

# Hepatitis B immunoglobulin (HBIG) withdrawal from combination lamivudine (LAM)/HBIG prophylaxis in liver transplant recipients

<b>Submission date</b> 19/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 12/10/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 11/04/2017	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr David Mutimer

**Contact details**  
Liver Unit  
Queen Elizabeth Hospital  
Edgbaston  
Birmingham  
United Kingdom  
B15 2TH

## Additional identifiers

**Protocol serial number**  
RG\_05-002

## Study information

**Scientific Title**  
Hepatitis B immunoglobulin (HBIG) withdrawal from combination lamivudine (LAM)/HBIG prophylaxis in liver transplant recipients

**Acronym**

HBIG/ADV

**Study objectives**

The aim of this study is to evaluate the safety of HBIG withdrawal from patients who are receiving combination lamivudine/HBIG following liver transplantation. The proposed study design will examine the following hypotheses:

1. It is safe to withdraw HBIG from the existing prophylaxis regime for recipients who had a low pre-treatment serum HBV titre
2. Combination lamivudine and adefovir dipivoxil will provide a safe alternative to lamivudine and HBIG prophylaxis for recipients who had a high pre-treatment serum HBV titre

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Hepatitis B virus infected liver transplant recipients

**Interventions**

Patients will be stratified into two groups according to the pre-lamivudine treatment, pre-transplantation serum HBV DNA titre (baseline viral load):

Stratum A: in high-risk patients: HBV DNA more than or equal to  $1.0 \times 10^6$  genomic copies/ml or patients who had detectable serum HBV DNA measured with hybridisation assays. (Patients who have not serum HBV DNA measured before commencement of lamivudine treatment may be included in the study, but must enter stratum A).

Patients will be randomised (1:1) into two groups:

Arm 1: LAM 100 mg QD + HBIG (according to each participating units existing protocol) for 2 years, with ADV being used as a rescue therapy

Arm 2: LAM 100 mg QD + ADV 10 mg QD for 2 years

Stratum B: in low-risk patients (HBV DNA less than  $1.0 \times 10^6$  genomic copies/ml)

Arm 3: LAM 100 mg QD only for 2 years (ADV will function as a rescue medication after withdrawal of HBIG)

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

The incidence of emergence of detectable serum HBV DNA during prophylaxis (more than or equal to 200 copies/ml HBV DNA).

**Key secondary outcome(s)**

The response of serum HBV DNA and outcome of HBV infection for those patients who require adefovir dipivoxil rescue

**Completion date**

01/10/2011

**Eligibility**

**Key inclusion criteria**

1. Male or female patients 18 to 75 years of age
2. Patients with serum HBsAg negativity and HBV DNA negativity (<200 copies/mL as per Roche COBAS AMPLICOR HBV MONITOR)
3. Patients have received a liver transplantation and have been successfully treated with lamivudine and HBIg for at least 12 months
4. Females of childbearing potential must have a negative urine pregnancy test at screening. Pre-menopausal females who are using effective methods of contraception and who agree to continue to do so for the duration of the study medication dosing and for 30 days after the last dose of study medication will be able to participate. Post-menopausal females will be eligible for enrollment
5. Confirmation that sexually active males must be practicing acceptable methods of contraception (vasectomy, condom, monogamous relationship with a female partner who practices an acceptable method of contraception) during the treatment period
6. Able to give written informed consent and comply with the requirements of the study

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. Lactating females or females with a positive pregnancy test
2. History of hypersensitivity to HBIg, lamivudine or adefovir dipivoxil. HCV, hepatitis delta virus (HDV), and/or human immunodeficiency virus (HIV) seropositive

3. Evidence of active liver disease due to other causes (e.g. Wilsons disease, hemochromatosis, autoimmune hepatitis, hepatitis C or hepatitis D co-infection, known HIV positivity, alpha-1 antitrypsin deficiency, alcoholic liver disease, obesity-induced liver disease, drug-related liver diseases)
4. Previous participation in an investigational trial involving administration of any investigational compound within 3 months prior to the study screening
5. Clinically relevant alcohol or drug use or history of alcohol or drug use considered by the investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events
6. Therapy with nephrotoxic drugs (e.g. aminoglycosides, amphotericin B, vancomycin, cidofovir, foscarnet, cis-platin, pentamidine) or competitors of renal excretion (e.g. probenecid) within 2 months prior to study screening or the expectation that subject will receive these during the course of the study, unless clinically mandated
7. The use of antiviral therapy with agents demonstrating potential anti-HBV activity within the previous 3 months (e.g. adefovir dipivoxil, famciclovir, lobucavir, emtricitabine, DAPD, LFMAU, entecavir, ganciclovir, tenofovir or others), other than lamivudine and HBIg

**Date of first enrolment**

01/10/2005

**Date of final enrolment**

01/10/2011

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre****Liver Unit**

Birmingham

United Kingdom

B15 2TH

## Sponsor information

**Organisation**

University of Birmingham (UK)

**ROR**

<https://ror.org/03angcq70>

# **Funder(s)**

## **Funder type**

Industry

## **Funder Name**

Educational Grant from Gilead Sciences Inc

# **Results and Publications**

## **Individual participant data (IPD) sharing plan**

### **IPD sharing plan summary**

Not provided at time of registration